Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
BIO89-100-131: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 8, 2026
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 8, 2026
Experiences of individuals who have participated in Crystal Meth Anonymous: a qualitative study
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 31, 2025
Tirzepatide’s Role in Postmenopausal HR+ Breast Cancer Survivors
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 23, 2025
A012301- LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 22, 2025
Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 16, 2025
Gene Therapy for Alpha 1-Antitrypsin Deficiency
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 16, 2025
Assessment of attitudes towards PSA screening and decision aids
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 16, 2025
Pilot of an Integrated Treatment for Comorbid PTSD and Chronic Pain
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 16, 2025
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025